With over 15 years of expertise and client success, Varinac will play a crucial role in the company’s rapid growth.
ROCKVILLE, MD / ACCESSWIRE / December 15, 2023 / Theralogix, a national leader in the supplement industry, announces the addition of Nicholas Varinac to its dynamic sales team. Varinac will assume the position of Regional Sales Manager for the Midwest territory.
Varinac began his career as a National Account Executive directly responsible for acquiring, managing, and expanding customer accounts totaling $3.6 million in revenue for a global Fortune 500 company. Throughout his career, Varinac has been regarded as a relationship-building expert with a strategic and thoughtful approach.
Varinac has had proven success building business revenue and relationships while providing solutions in exceptionally dynamic industries. He is focused on educating providers through a consultative coaching approach using excellent communication, active listening, and analytical skills. Varinac is dedicated to earning trust, achieving provider retention, and driving consistent results.
As a dedicated Relationship Manager and Senior Physician Liaison, Varinac was responsible for driving new business with healthcare providers in spaces such as Dermatology, Rheumatology, Podiatry, OBGYN, and Internal Medicine. His success with healthcare providers attests to his exceptional qualifications for effectively engaging with Theralogix providers and expanding the provider base.
Theralogix sets the standard for premium, research-backed nutritional supplements. Each product is independently certified by NSF® International for content accuracy and freedom from contaminants. Theralogix has been a top physician-recommended brand for over two decades. For more information about Theralogix and its range of evidence-based products, please visit the Theralogix Website.
Contact Information
Shannon Mahon
smahon@theralogix.com
301.464.7210
SOURCE: Theralogix
View the original press release on newswire.com.
SEATTLE, Dec. 06, 2025 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage…
– Data support initiation of a combination cohort in the ongoing Phase 1 clinical trial…
SPRING, Texas, Dec. 06, 2025 (GLOBE NEWSWIRE) -- Io Therapeutics, Inc., a privately held pharmaceutical…
Ficerafusp alfa 750mg QW in combination with pembrolizumab demonstrates consistent overall response rate and safety…
TUS+VEN+AZA triplet frontline therapy demonstrates high rates of efficacy and MRD-negative remissions in newly diagnosed…
Demonstrated meaningful overall anemia responses across all patient subgroups, regardless of baseline transfusion status Anemia response…
